Go Deep
aTyr Pharma, Inc.
aTyr Pharma, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,767 | -0.3 | 0.37 | 0.23 | 17.41 |
| Oct 2026 | 22,821 | -0.3 | 0.35 | 0.23 | 16.48 |
| Oct 2026 | 21,034 | -0.3 | 0.34 | 0.23 | 16.28 |
| Oct 2026 | 21,025 | -0.3 | 0.35 | 0.23 | 16.43 |
| Oct 2026 | 21,030 | -0.3 | 0.35 | 0.23 | 16.30 |
| Oct 2026 | 21,043 | -0.3 | 0.34 | 0.23 | 16.05 |
aTyr Pharma, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 190,000.0 |
| Net Profit | -10,309,000.0 | -10,791,000.0 | -13,963,000.0 | -25,744,000.0 |
| EPS | -0.1 | -0.1 | -0.1 | -0.3 |
aTyr Pharma, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 190,000.0 | 235,000.0 | 353,000.0 | 10,386,000.0 |
| Net Profit | -74,118,000.0 | -64,023,000.0 | -50,389,000.0 | -45,338,000.0 |
| EPS | -0.8 | -0.9 | -0.9 | -1.6 |
aTyr Pharma, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 93,003,000.0 | 96,830,000.0 | 120,653,000.0 | 95,786,000.0 | — |
| Total Liabilities | 25,715,000.0 | 26,998,000.0 | 30,183,000.0 | 24,502,000.0 | — |
| Total Equity | 67,480,000.0 | 70,019,000.0 | 90,658,000.0 | 71,464,000.0 | — |
Owes vs Owns
aTyr Pharma, Inc. owed $0.30 for every $1 it owned in Jun 2026, up from $0.26 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.30× | 0.28× | 0.28× | 0.25× | 0.26× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
aTyr Pharma, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 84.6%Receivables 0.9%Fixed assets (tangible) 11.2%Other assets 3.3%
How it's funded — Dec 2025
Short-term debt 1.6%Long-term debt 11.4%Payables 4.2%Other liabilities 10.5%Shareholders' equity 72.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 78.7 | 72.1 | 98.2 | 66.1 |
| Receivables | 0.9 | 1.7 | 2.4 | 11.8 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 10.4 | 11.9 | 14.0 | 11.6 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 3.1 | 11.1 | 6.0 | 6.3 |
| Liabilities & equity | ||||
| Short-term debt | 1.5 | 1.3 | 1.3 | 0.9 |
| Long-term debt | 10.6 | 12.0 | 13.8 | 10.6 |
| Payables | 3.9 | 4.3 | 3.5 | 3.1 |
| Other liabilities | 9.8 | 9.4 | 11.6 | 9.9 |
| Shareholders' equity | 67.3 | 69.8 | 90.5 | 71.3 |
| Net tangible assets | 67.5 | 70.0 | 90.7 | 71.5 |
aTyr Pharma, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -61,986,000.0 | -69,119,000.0 | -33,221,000.0 | -41,886,000.0 | — |
| Investing Activities | -5,053,000.0 | 17,233,000.0 | -20,127,000.0 | 47,245,000.0 | — |
| Financing Activities | 66,011,000.0 | 39,864,000.0 | 66,230,000.0 | 5,451,000.0 | — |